Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT)

  • Mancia G
  • Brown M
  • Castaigne A
 et al. 
  • 27


    Mendeley users who have this article in their library.
  • 141


    Citations of this article.


To investigate the impact of treatment on cardiovascular mortality and morbidity, we assessed outcomes in patients with hypertension and diabetes who received co-amilozide or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension. Participants had to be 55 to 80 years of age, with hypertension (> or =150/95 or > or =160 mm Hg) and at least one additional cardiovascular risk factor. Patients received 30 mg nifedipine once daily or co-amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily. Doses were doubled if target blood pressures (

Author-supplied keywords

  • Calcium channel blockers
  • Diabetes mellitus
  • Diuretics
  • Morbidity
  • Mortality
  • Nifedipine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free